Pharos iBio, a leading artificial intelligence (AI) driven drug development firm, announced on Monday its participation in Bio Europe Spring 2026. The event, scheduled for March 23-25 in Lisbon, Portugal, will serve as a platform for the company to explore global collaboration opportunities for its key cancer treatment pipelines.
During the conference, Pharos iBio will engage in partnering meetings with international pharmaceutical and biotech companies, highlighting its acute myeloid leukemia (AML) treatment, Rasmotinib, and its innovative therapy for refractory solid tumors, PHI-501.
The company’s strategy centers on leveraging its research and development achievements to strengthen relationships with global pharmaceutical giants and investors, while actively pursuing technology transfer opportunities.
Rasmotinib, designed to Target FLT3 mutations present in 30% of AML patients, has shown promising results in a recently concluded global Phase 1 clinical trial, demonstrating both efficacy and safety.
In a Phase 1b trial involving patients with relapsed and refractory AML, Rasmotinib achieved an impressive 50% overall complete response (CRc) rate. This outcome is particularly noteworthy given the severity of conditions among many trial participants, outperforming competing drugs.
Lasmotinib’s potential has been recognized by regulatory bodies, having received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), marking a significant step towards commercialization.
PHI-501, another promising candidate in Pharos iBio’s portfolio, targets solid tumors with BRAF, KRAS, and NRAS mutations, including colorectal cancer and melanoma. The drug entered Phase 1 clinical trials in South Korea earlier this year.
Utilizing its proprietary AI drug development platform, Chemiverse, and the indication expansion module, DeepRECOM, Pharos iBio is broadening PHI-501’s potential applications. The company is exploring its efficacy in treating various solid tumors, including refractory lung cancer, colorectal cancer, and malignant melanoma.
Bio Europe Spring stands as Europe’s premier springtime partnering event for the biotech industry. It brings together professionals from pharmaceutical and biotech companies, along with investment experts, to share research findings and discuss strategic collaborations. This year’s event is expected to draw over 3,700 industry participants from more than 60 countries, offering extensive opportunities for partnering meetings and networking.
Dr. Kim Kyu-tae, Chief Business Officer of Pharos iBio and head of its Australian operations, emphasized the innovative nature of their pipeline. He stated that Lasmotinib and PHI-501 represent cutting-edge treatment strategies that have the potential to overcome limitations in current therapies. At this event, it aims to explore collaboration possibilities that could lead to global commercialization of these promising drugs.
